CVRdatabase
Menu

Hemab ApS

Private limited companyCVR 40837590FrederiksbergActive

Hemab ApS is a private limited company, based in Frederiksberg, active in manufacture of pharmaceutical preparations, founded in 2019. The company made a loss in both 2024 and 2025, most recently DKK 61.4m. With 46 employees, the company is about 5 times larger than the industry median. Equity grew to DKK 183.4m in 2025.

Follow
PDF reportCompare

Key figures · financial year 2025

Net profit−DKK 61.4m−27.3% vs. 2024
EquityDKK 183.4m+107.6% vs. 2024
Employees46latest month from CVR

What has changed

calculated from recorded figures and dates

Financials: 2025 against 2024

  • The loss grew: from DKK 48.2m to DKK 61.4m (2024 → 2025).
  • Equity rose 108% (2024 → 2025), to DKK 183.4m.

Employees

  • 21 more employees than a year earlier: 46 (07/2026) against 25 (07/2025).

Management and owners, last 24 months

  • New in management: Joseph Anderson (board member, 23/10/2025).
  • Stepped down: Mårten Steen (board member, 23/10/2025), Laura Anne Tadvalkar (board member, 08/05/2026) and Jørgen Søberg Petersen (board member, 10/04/2026) (+3).
  • New owners registered: Hemab Therapeutics Holdings, Inc. (30/03/2026), Novo Holdings A/S (23/10/2025) and RA Capital Healthcare Fund, L.P. (23/10/2025) (+5).
  • No longer registered as owner: Novo Holdings A/S (22/10/2025), Ebumab Holding ApS (23/10/2025) and RA Capital Nexus Fund II, L.P. (23/10/2025) (+12).

Registrations, last 24 months

  • 23/10/2025: Share capital changed from 734,414 DKK to 1,247,405 DKK

Calculated from the latest two annual reports in sequence and from registrations in CVR. A figure that is missing in either year gives no line, and we derive no figures.

Financial statements

Financial years 2020–2025 · amounts in DKK thousand

Equity and net profit

−DKK 200m−DKK 150m−DKK 100m−DKK 50mDKK 0DKK 50mDKK 100mDKK 150mDKK 200m202020212022202320242025
EquityNet profit
Financial figures for Hemab ApS
202020212022202320242025Change
Revenue0not statednot statednot statednot statednot stated–
Gross profit−10,075––––––
Operating profit (EBIT)−10,256−41,156−161,480––––
Profit before tax−10,550−40,134−161,256––−62,380–
Net profit−8,139−35,163−156,407−22,569−48,212−61,353−27.3%
Total assets14,49678,69632,916141,99996,902195,363+101.6%
Equity10,53268,0356,101136,56688,354183,422+107.6%
Liabilities3,96410,66126,8155,4338,54811,941+39.7%
Cash and cash equivalents12,54368,03223,12158,14174,33787,974+18.3%
Average number of employees1310213654+50%

Source: annual reports filed with the Danish Business Authority (XBRL). Group figures; change is the latest year against the year before. “–” means the figure is not stated in the annual report. Revenue is not stated for 2021, 2022, 2023, 2024, 2025: smaller companies may omit it, and we do not derive it from other figures.

Download the figures as CSV · free with an account, amounts in whole DKK

−DKK 160m−DKK 140m−DKK 120m−DKK 100m−DKK 80m−DKK 60m−DKK 40m−DKK 20mDKK 0202020212022202320242025
Net profitMedian, the industry (59 companies)

Signals from the financial statements

calculated from the 2025 figures

  • Loss for 6 years in a row

    Net result has been negative in 2020–2025.

    How is this calculated?

    Net result is negative in the two or more latest annual reports in a row.

The signals are rules applied to the figures in the annual reports. They are not an assessment or credit rating of the company. See Data and method.

Annual reports

6 financial years
Annual reports for Hemab ApS
Financial yearPeriodPublishedFigures forDocuments
202501/01/2025 – 31/12/202530/06/2026The groupPDF not statedXBRL
202401/01/2024 – 31/12/202423/06/2025The groupPDFXBRL
202301/01/2023 – 31/12/202326/06/2024The groupPDFXBRL
202201/01/2022 – 31/12/202203/07/2023The companyPDFXBRL
202101/01/2021 – 31/12/202106/07/2022The companyPDFXBRL
202027/09/2019 – 31/12/202011/05/2021The companyPDFXBRL

The figures from all the annual reports are shown on this page. The documents themselves (PDF and XBRL, the machine-readable edition) are downloaded with a Pro account: sign in or create a free account, and then choose Pro. XBRL is the edition the figures on the page are read from.

Employees

monthly figures from CVR
0102030405008/2309/2310/2311/2312/2301/2402/2403/2404/2405/2406/2407/2408/2409/2410/2411/2412/2401/2502/2503/2504/2505/2506/2507/2508/2509/2510/2511/2512/2501/2602/2603/2604/2605/2606/2607/26
Employees

Position in the industry

59 companies in the database

Comparison with the other companies in manufacture of pharmaceutical preparations based on the latest financial year.

EquityDKK 183.4mNo. 14 of 59
Better than 78% of the companies in the industry
Number of employees46No. 17 of 59
Better than 72% of the companies in the industry

Industry median: gross profit DKK 2.8m, net profit −DKK 2.2m, equity DKK 5.2m, 10 employees.

DKK 266kDKK 8.3mDKK 258mDKK 8bnDKK 79.6bn
Distribution of gross profit for 34 companies in the industry (latest financial year, logarithmic scale).

Compared with similar companies

size, age and company form
Rank among similar companies
GroupGross profitEquity
Companies with 20–49 employees9,922 companies in the comparisonnot stated
No. 214of 9,922
Better than 98%
Companies that are between 5 and 14 years old33,688 companies in the comparisonnot stated
No. 436of 33,687
Better than 99%
All companies of type ApS66,508 companies in the comparisonnot stated
No. 641of 66,505
Better than 99%

The rank is calculated among companies in the database with a figure for the latest financial year, and is shown only for groups of at least ten companies.

Compare with the industry

Manufacture of pharmaceutical preparations
Gross profit
  1. Hemab ApS−DKK 10.1m
  2. Novo Nordisk A/SDKK 250.3bn
  3. H. Lundbeck A/SDKK 20.4bn
Net profit
  1. Hemab ApS−DKK 61.4m
  2. Novo Nordisk A/SDKK 102.4bn
  3. H. Lundbeck A/SDKK 3.2bn
Equity
  1. Hemab ApSDKK 183.4m
  2. Novo Nordisk A/SDKK 194bn
  3. H. Lundbeck A/SDKK 24.9bn
Employees
  1. Hemab ApS46
  2. Novo Nordisk A/S27,279
  3. H. Lundbeck A/S2,261

Latest financial year per company. Choose up to three companies from the largest in the industry.

Owners and group

from the Public Ownership Register
Owners
  • Hemab Therapeutics Holdings, Inc.100%
Hemab ApS

Management

6 active registrations

Executive management

Executive management at Hemab ApS
NameRoleAppointed
Mads Nikolaj Behrndt-EriksenDirector01/09/2021
Benny SørensenCEO10/01/2022

Board of directors

Board of directors at Hemab ApS
NameRoleAppointed
Linda Catharina BainBoard member10/01/2022
John Michael MaraganoreChair of the board10/01/2022
Benny SørensenBoard member15/02/2023
Akshay Krishnadas VaishnawBoard member16/01/2024
Founders
Ebumab Holding ApS
Former management (17)
Former management at Hemab ApS
NameRoleAppointedResigned
Hans Heugh WandallBoard member27/09/201921/06/2020
Johan Henrik FaberDirector27/09/201901/03/2023
Johan Henrik FaberBoard member27/09/201922/07/2021
Kim Stengaard HolmstedChair of the board27/09/201922/06/2020
Thomas Dal Stenfeldt BatchelorBoard member27/09/201920/11/2020
Hans Heugh WandallChair of the board22/06/202020/11/2020
Søren Erik BjørnBoard member22/06/202020/11/2020
Benny SørensenBoard member20/11/202022/07/2021
Camilla Petrycer HansenBoard member20/11/202022/07/2021
Jørgen Søberg PetersenChair of the board20/11/202009/01/2022
Thomas Dal Stenfeldt BatchelorBoard member22/07/202115/02/2023
Mårten SteenBoard member22/07/202123/10/2025
Laura Anne TadvalkarBoard member22/07/202108/05/2026
Jørgen Søberg PetersenBoard member10/01/202210/04/2026
Daniel BeckerBoard member15/02/202310/04/2026
Uya ChuluunbaatarBoard member15/02/202310/04/2026
Joseph AndersonBoard member23/10/202510/04/2026

Signing rule: Selskabet tegnes af en direktør eller af den samlede bestyrelse.

Address and production units

1 active production units

Nordre Fasanvej 215
2000 Frederiksberg

Frederiksberg Municipality · Postcode 2000

Other companies at the address (8)

  • Sparrow Quantum ApSManufacture of computers and peripheral equipment
  • Adcendo ApSResearch and experimental development on natural sciences and engineering
  • Orbis Medicines ApSResearch and experimental development on natural sciences and engineering
  • Minervax ApSResearch and experimental development on natural sciences and engineering
  • Inprother ApSResearch and experimental development on natural sciences and engineering
Production units
Production unitAddressEmployeesP number
Hemab ApSNordre Fasanvej 215, 2000 Frederiksberg491025104265

Purpose

Selskabets formål er at drive virksomhed indenfor forskning, udvikling og markedsføring af produkter til brug for diagnosticering, behandling og/eller forebyggelse af hæmatologiske sygdomme med risiko for øget blødning eller udvikling af blodpropper.

The purpose is quoted from the register in Danish.

Changes year by year

124 registered events
202614 changesaccounts 1 · management 5 · ownership 8
  • Annual report for 2025 published
  • Laura Anne Tadvalkar stepped down as board member
  • Joseph Anderson stepped down as board member
  • Daniel Becker stepped down as board member
  • Uya Chuluunbaatar stepped down as board member
  • Jørgen Søberg Petersen stepped down as board member
  • Hemab Therapeutics Holdings, Inc. registered as owner (100%)
  • SMALLCAP World Fund, Inc. is no longer registered as owner
  • Sofinnova Crossover II S.L.P. is no longer registered as owner
  • DEEP TRACK BIOTECHNOLOGY MASTER FUND, LTD. is no longer registered as owner
  • AI DEN-MAB LLC is no longer registered as owner
  • HealthCap VIII L.P. is no longer registered as owner
  • Novo Holdings A/S is no longer registered as owner
  • RA Capital Healthcare Fund, L.P. is no longer registered as owner
202519 changescapital 1 · management 2 · ownership 15 · accounts 1
  • Share capital changed from 734,414 DKK to 1,247,405 DKK
  • Joseph Anderson appointed board member
  • Mårten Steen stepped down as board member
  • SMALLCAP World Fund, Inc. registered as owner (5%)
  • Sofinnova Crossover II S.L.P. registered as owner (5%)
  • DEEP TRACK BIOTECHNOLOGY MASTER FUND, LTD. registered as owner (5%)
  • AI DEN-MAB LLC registered as owner (10%)
  • HealthCap VIII L.P. registered as owner (5%)
  • Novo Holdings A/S registered as owner (15%)
  • RA Capital Healthcare Fund, L.P. registered as owner (10%)
  • Ebumab Holding ApS is no longer registered as owner
  • AVORO VENTURES FUND L.P. is no longer registered as owner
  • RA Capital Nexus Fund II, L.P. is no longer registered as owner
  • DEEP TRACK BIOTECHNOLOGY MASTER FUND, LTD. is no longer registered as owner
  • AI DEN-MAB LLC is no longer registered as owner
  • HealthCap VIII L.P. is no longer registered as owner
  • RA Capital Healthcare Fund, L.P. is no longer registered as owner
  • Novo Holdings A/S is no longer registered as owner
  • Annual report for 2024 published
20243 changesaccounts 1 · address 1 · management 1
  • Annual report for 2023 published
  • Moved to Nordre Fasanvej 215, 2000 Frederiksberg
  • Akshay Krishnadas Vaishnaw appointed board member
202323 changesaccounts 1 · management 5 · capital 2 · ownership 15
  • Annual report for 2022 published
  • Johan Henrik Faber stepped down as director
  • Share capital changed from 292,209 DKK to 734,414 DKK
  • Daniel Becker appointed board member
  • Benny Sørensen appointed board member
  • Uya Chuluunbaatar appointed board member
  • Thomas Dal Stenfeldt Batchelor stepped down as board member
  • Ebumab Holding ApS registered as owner (5%)
  • AVORO VENTURES FUND L.P. registered as owner (5%)
  • DEEP TRACK BIOTECHNOLOGY MASTER FUND, LTD. registered as owner (5%)
  • AI DEN-MAB LLC registered as owner (15%)
  • HealthCap VIII L.P. registered as owner (10%)
  • RA Capital Healthcare Fund, L.P. registered as owner (10%)
  • RA Capital Nexus Fund II, L.P. registered as owner (5%)
  • Novo Holdings A/S registered as owner (20%)
  • Ebumab Holding ApS is no longer registered as owner
  • HealthCap VIII L.P. is no longer registered as owner
  • RA Capital Healthcare Fund, L.P. is no longer registered as owner
  • Novo Holdings A/S is no longer registered as owner
  • RA Capital Nexus Fund II, L.P. is no longer registered as owner
  • Share capital changed from 251,143 DKK to 292,209 DKK
  • Ebumab Holding ApS registered as owner (10%)
  • Ebumab Holding ApS is no longer registered as owner
202222 changescapital 2 · ownership 14 · accounts 1 · management 5
  • Share capital changed from 189,543 DKK to 251,143 DKK
  • Ebumab Holding ApS registered as owner (15%)
  • HealthCap VIII L.P. registered as owner (20%)
  • RA Capital Healthcare Fund, L.P. registered as owner (20%)
  • HealthCap VIII L.P. is no longer registered as owner
  • RA Capital Healthcare Fund, L.P. is no longer registered as owner
  • Ebumab Holding ApS is no longer registered as owner
  • Annual report for 2021 published
  • Share capital changed from 127,943 DKK to 189,543 DKK
  • Novo Holdings A/S registered as owner (25%)
  • HealthCap VIII L.P. registered as owner (15%)
  • RA Capital Healthcare Fund, L.P. registered as owner (15%)
  • Ebumab Holding ApS registered as owner (20%)
  • Ebumab Holding ApS is no longer registered as owner
  • HealthCap VIII L.P. is no longer registered as owner
  • RA Capital Healthcare Fund, L.P. is no longer registered as owner
  • Novo Holdings A/S is no longer registered as owner
  • Benny Sørensen appointed ceo
  • John Michael Maraganore appointed chair of the board
  • Jørgen Søberg Petersen appointed board member
  • Linda Catharina Bain appointed board member
  • Jørgen Søberg Petersen stepped down as chair of the board
202116 changesmanagement 7 · capital 1 · ownership 7 · accounts 1
  • Mads Nikolaj Behrndt-Eriksen appointed director
  • Share capital changed from 66,343 DKK to 127,943 DKK
  • Mårten Steen appointed board member
  • Thomas Dal Stenfeldt Batchelor appointed board member
  • Laura Anne Tadvalkar appointed board member
  • Camilla Petrycer Hansen stepped down as board member
  • Benny Sørensen stepped down as board member
  • Johan Henrik Faber stepped down as board member
  • Ebumab Holding ApS registered as owner (25%)
  • HealthCap VIII L.P. registered as owner (10%)
  • RA Capital Healthcare Fund, L.P. registered as owner (10%)
  • RA Capital Nexus Fund II, L.P. registered as owner (5%)
  • Novo Holdings A/S registered as owner (33.33%)
  • Ebumab Holding ApS is no longer registered as owner
  • Novo Holdings A/S is no longer registered as owner
  • Annual report for 2020 published
202020 changescapital 2 · management 10 · ownership 7 · name 1
  • Share capital changed from 43,000 DKK to 66,343 DKK
  • Jørgen Søberg Petersen appointed chair of the board
  • Camilla Petrycer Hansen appointed board member
  • Benny Sørensen appointed board member
  • Hans Heugh Wandall stepped down as chair of the board
  • Søren Erik Bjørn stepped down as board member
  • Thomas Dal Stenfeldt Batchelor stepped down as board member
  • Ebumab Holding ApS registered as owner (50%)
  • Novo Holdings A/S registered as owner (33.33%)
  • GV1 Holding ApS is no longer registered as owner
  • Ebumab Holding ApS is no longer registered as owner
  • Name changed from Ebumab Hemophilia ApS to Hemab ApS
  • Share capital changed from 40,000 DKK to 43,000 DKK
  • Hans Heugh Wandall appointed chair of the board
  • Søren Erik Bjørn appointed board member
  • Kim Stengaard Holmsted stepped down as chair of the board
  • Ebumab Holding ApS registered as owner (90%)
  • GV1 Holding ApS registered as owner (5%)
  • Hans Heugh Wandall stepped down as board member
  • Ebumab Holding ApS is no longer registered as owner
20197 changesfounded 1 · management 5 · ownership 1
  • Registered as Ebumab Hemophilia ApS
  • Johan Henrik Faber appointed director
  • Thomas Dal Stenfeldt Batchelor appointed board member
  • Kim Stengaard Holmsted appointed chair of the board
  • Johan Henrik Faber appointed board member
  • Hans Heugh Wandall appointed board member
  • Ebumab Holding ApS registered as owner (100%)

Related companies

Same industry in Frederiksberg

See all →

Same people in management

Largest in the industry

See all →

Source and updates

The information comes from the Danish Central Business Register (Danish Business Authority) and from annual reports filed with the Danish Business Authority. Last synchronised 24/10/2026.

View in CVRReport a correction